A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO COMPARE THE PHARMACOKINETICS OF PF-07923568 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT
Latest Information Update: 23 Mar 2025
At a glance
- Drugs Sisunatovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 02 Apr 2024 Status changed from recruiting to completed.
- 11 Feb 2024 Status changed from active, no longer recruiting to recruiting.
- 18 Jan 2024 Planned End Date changed from 15 Dec 2023 to 7 Feb 2024.